TRIM5alpharh expression restricts HIV-1 infection in lentiviral vector-transduced CD34+-cell-derived macrophages - PubMed (original) (raw)
TRIM5alpharh expression restricts HIV-1 infection in lentiviral vector-transduced CD34+-cell-derived macrophages
Joseph Anderson et al. Mol Ther. 2005 Oct.
Free article
Abstract
Species-specific innate resistance against viral infections offers novel avenues for antiviral therapeutic and prophylactic approaches. The retroviral and lentiviral restriction factors Ref1 and Lv1 are variants of the tripartite motif protein TRIM5alpha, a component of cytoplasmic bodies. TRIM5alpha severely restricts productive retroviral infections at the postentry and preintegration steps by destabilizing the incoming viral capsid via ubiquitination. Using this approach, resistance to HIV-1 infection could be conferred by TRIM5alpha(rh) expression in otherwise susceptible cells. Here we show that stable expression of simian TRIM5alpha(rh) via a lentiviral vector in a permissive cell culture line, Magi-CXCR4, conferred resistance to HIV-1. To translate these findings into a stem cell gene therapy setting, the TRIM5alpha(rh) transgene was stably introduced into CD34(+) hematopoietic progenitor cells to derive transgenic macrophages. Upon viral challenge, TRIM5alpha(rh)-expressing macrophages were highly resistant to HIV-1 infection compared to control cells. Human macrophages expressing TRIM5alpha(rh) were also found to be phenotypically and functionally normal, expressing the characteristic surface markers CD14, CD4, CCR5, CXCR4, MHC II, and B7.1. These results demonstrate that the species-specific restriction factor TRIM5alpha(rh) is effective in conferring HIV-1 resistance in a stem cell setting, thus paving the way for its application in AIDS gene therapy.
Similar articles
- CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection.
Anderson J, Akkina R. Anderson J, et al. Retrovirology. 2005 Aug 18;2:53. doi: 10.1186/1742-4690-2-53. Retrovirology. 2005. PMID: 16109172 Free PMC article. - Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy.
Anderson JS, Javien J, Nolta JA, Bauer G. Anderson JS, et al. Mol Ther. 2009 Dec;17(12):2103-14. doi: 10.1038/mt.2009.187. Epub 2009 Aug 18. Mol Ther. 2009. PMID: 19690520 Free PMC article. - Retroviral restriction factors TRIM5α: therapeutic strategy to inhibit HIV-1 replication.
Zhang J, Ge W, Zhan P, De Clercq E, Liu X. Zhang J, et al. Curr Med Chem. 2011;18(17):2649-54. doi: 10.2174/092986711795933687. Curr Med Chem. 2011. PMID: 21568899 Review. - Using TRIM5α as an HIV therapeutic: the alpha gene?
Anderson JS. Anderson JS. Expert Opin Biol Ther. 2013 Jul;13(7):1029-38. doi: 10.1517/14712598.2013.779251. Epub 2013 Mar 12. Expert Opin Biol Ther. 2013. PMID: 23480791 Review.
Cited by
- Novel approaches to inhibiting HIV-1 replication.
Adamson CS, Freed EO. Adamson CS, et al. Antiviral Res. 2010 Jan;85(1):119-41. doi: 10.1016/j.antiviral.2009.09.009. Epub 2009 Sep 24. Antiviral Res. 2010. PMID: 19782103 Free PMC article. Review. - TRIM5alpha disrupts the structure of assembled HIV-1 capsid complexes in vitro.
Black LR, Aiken C. Black LR, et al. J Virol. 2010 Jul;84(13):6564-9. doi: 10.1128/JVI.00210-10. Epub 2010 Apr 21. J Virol. 2010. PMID: 20410272 Free PMC article. - Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches.
Santa-Marta M, de Brito PM, Godinho-Santos A, Goncalves J. Santa-Marta M, et al. Front Immunol. 2013 Oct 24;4:343. doi: 10.3389/fimmu.2013.00343. Front Immunol. 2013. PMID: 24167505 Free PMC article. Review. - The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication.
Wang X, Ao Z, Chen L, Kobinger G, Peng J, Yao X. Wang X, et al. J Virol. 2012 Apr;86(7):3777-86. doi: 10.1128/JVI.06594-11. Epub 2012 Feb 1. J Virol. 2012. PMID: 22301159 Free PMC article. - Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART.
Peterson CW, Younan P, Jerome KR, Kiem HP. Peterson CW, et al. Gene Ther. 2013 Jul;20(7):695-702. doi: 10.1038/gt.2012.98. Epub 2013 Jan 31. Gene Ther. 2013. PMID: 23364313 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous